A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging study of Efficacy and Safety of SAR441566 in Adults with Moderate to Severe Plaque Psoriasis
This research study is looking into a new medicine, known as SAR441566, for adults who have moderate to severe plaque psoriasis. Psoriasis is a skin condition that causes red, scaly patches. This study aims to find out how well SAR441566 works to improve psoriasis symptoms and whether it is safe for people to use. Some participants will receive the new medicine at different dose levels, while others will receive a placebo (a dummy medicine with no active ingredient). This helps researchers compare the effects accurately. The main goal is to see how many people have a significant improvement in their psoriasis after 12 weeks of treatment.
At a glance
What is this study about?
Imagine you have plaque psoriasis, a condition where your skin develops red, scaly patches. Doctors are constantly working to find better ways to help people manage their psoriasis. This study is testing a new medicine called SAR441566 to see if it could be one of those better ways.
It's a 'Phase 2' study, which means it's one of the earlier steps in testing a new medicine. At this stage, doctors are mainly focused on two things: finding out how well the new medicine works to improve psoriasis symptoms, and checking if it's safe for people to take. They're also trying to figure out the right amount, or 'dose,' of the medicine that works best.
To make sure the results are fair and accurate, some people in the study will get the new medicine, and others will get what's called a 'placebo.' A placebo looks just like the real medicine but contains no active ingredients. Neither you nor your doctor will know whether you're getting the active medicine or the placebo – this is called 'double-blind.' This helps to ensure that any improvements or side effects are truly due to the medicine and not other factors. The information gathered from this study will help decide if this medicine should be tested in even larger studies in the future.
Key takeaways
- This study tests a new medicine (SAR441566) for moderate to severe plaque psoriasis.
- It's a Phase 2 study focused on how well the medicine works and its safety.
- Some participants will receive the new medicine, others a placebo.
- The main goal is to see significant improvement in psoriasis after 12 weeks.
- Adults (18+) with moderate to severe plaque psoriasis are eligible.
- Participation involves regular check-ups and monitoring over about 12 weeks.
Who may be eligible?
To join this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
Because it's for people with plaque psoriasis, you would need to have symptoms that your doctor considers 'moderate to severe.' The study team will check your medical history and do some tests to make sure that taking part is safe and suitable for you.
There might be other specific reasons why someone couldn't join, for example, if they have certain other health conditions or are taking particular medications. The study team will discuss all these details with you properly.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have plaque psoriasis that your doctor considers moderate to severe?
- Are you available for regular clinic visits over a few months?
- Are you able to understand and agree to the rules of the study?
What does participation involve?
If you decide to take part in this study, you would receive the study medicine (or placebo) and have regular check-ups. These check-ups would involve doctors looking at your psoriasis, and you might have blood tests to see how the medicine is affecting your body. You'll also be asked about any side effects you might be experiencing.
The main part of the study where the medicine is given lasts for 12 weeks. During this time, you would have several visits to the study clinic for assessments. The study team will closely monitor your health throughout. The total duration of your involvement, including any follow-up after the medicine stops, will be explained in detail by the study team.
Potential risks and benefits
Locations (7)
- —UnverifiedSpain
- —UnverifiedGermany
- —UnverifiedHungary
- —UnverifiedPortugal
- —UnverifiedCzechia
- —UnverifiedPoland
- —UnverifiedBulgaria
Common questions
What is a 'Phase 2' study?
It's an early stage of testing a new medicine, aiming to see how well it works, how safe it is, and what dose is best.
What is a placebo?
A placebo is a 'dummy' medicine that looks like the real thing but has no active ingredients. It helps researchers compare effects.
Will I know if I'm getting the real medicine or the placebo?
No, neither you nor your study doctor will know. This is called 'double-blind' and helps keep the results fair.
What does 'moderate to severe' psoriasis mean?
It means your psoriasis is affecting a significant part of your body or is having a big impact on your daily life.
How long would I be in the study for?
The main treatment period is 12 weeks, with regular clinic visits during this time. The study staff will explain the full time commitment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.